Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.78 |
| ▸ | AXL | P30530 | 1/20 | 0.78 |
| ▸ | MERTK | Q12866 | 1/20 | 0.78 |
| ▸ | BCL2 | P10415 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189005 | 1.00 | PIK3CD (0.78) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL9928839 | 0.89 | PIK3CD (0.62) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL9967831 | 0.86 | PIK3CD (0.59) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL21517179 | 0.86 | PIK3CD (0.58) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL9929097 | 0.84 | PIK3CD (0.56) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL10278948 | 0.84 | PIK3CD (0.56) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL9929317 | 0.84 | PIK3CD (0.56) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL9929153 | 0.84 | PIK3CD (0.55) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL9928977 | 0.83 | PIK3CD (0.55) | PIK3CDAXLMERTKBCL2PIK3CG | |
| SCHEMBL2017408 | 0.83 | PIK3CD (0.64) | PIK3CDAXLMERTKBCL2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20210093638-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2021-04-01 | — | — | US | claimed |
| EP-3795152-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2021-03-24 | — | — | EP | claimed |
| EP-3129021-B1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORP (US) | 2020-09-23 | — | — | EP | claimed |
| CN-111494386-A | Treatment of B cell malignancies by combination of JAK and PI3K inhibitors | 因赛特公司 | 2020-08-07 | — | — | CN | claimed |
| EP-3660016-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2020-06-03 | — | — | EP | claimed |
| EP-2655374-B1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-10-23 | — | — | EP | claimed |
| EP-3129021-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2017-02-15 | — | — | EP | claimed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | claimed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | claimed |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-10-08 | — | — | US | claimed |
| US-9096600-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-04 | — | — | US | claimed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | claimed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | claimed |
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | PIK3CD 2/4885AXL 1575/4885MERTK 888/4885 |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | PIK3CD 2/4885AXL 1575/4885MERTK 888/4885 |
| US-20210093638-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.